Copy
February 5, 2019
Giving healthcare companies the exposure they deserve. Every Tuesday.
BioTuesdays Banner
Share
Tweet
Share
Forward
Greetings,

Closely-held Interface Biologics is the subject of our Feature this week as Kelley Dealhoy, VP of business development, discusses how the company is pegging future growth on biotech applications of its Epidel division, initially with a long-term implant for the treatment of posterior inflammatory eye diseases.

Of special interest in our Briefs section was Titan Pharmaceuticals (NASDAQ:TTNP) reporting a double-digit increase in shipments of Probuphine after it assumed responsibility for sales and marketing in mid-June 2018; the FDA performing a pre-approval inspection of IntelGenx’s (TSXV:IGX; OTCQX:IGXT) facility in Montreal in connection with the NDA for RIZAPORT, a VersaFilm oral soluble film, for the treatment of acute migraines; Lutronic Vision, a wholly-owned subsidiary of Lutronic Corporation (KOSDAQ:085370), initiating a preclinical trial to determine the optimal setting for its R:GEN laser for the treatment of Dry AMD; closely-held ArcherDX acquiring genetic testing lab, Baby Genes; and closely-held Triphase Accelerator optioning a preclinical oncology compound to Celgene (NASDAQ:CELG) for up to $1-billion.

In Wall Street news, HCW assumed coverage of Mesoblast (NASDAQ:MESO) at “buy” with a price target of $6.50, and downgraded AVEO Pharmaceuticals (NASDAQ:AVEO) to “neutral” from “buy” and reduced its price target to $1 from $9. In addition, Leerink downgraded scPharmaceuticals (NASDAQ:SCPH) to “market perform” from “outperform” and lowered its price target to $5 from $12. Also, HCW and Leerink lowered their price targets for AC Immune (NASDAQ:ACIU) to $8 and $11, respectively.

Your friends at BioTuesdays.

Feature
THIS WEEK'S FEATURE

Interface Biologics to focus future growth in biotech with local drug delivery platform

Interface Biologics
Kelley Dealhoy

Closely-held Interface Biologics, best known for improving the safety and efficacy of medical devices through its Endexo surface modification technology, is pegging its future growth on biotech, with an initial focus on unmet needs in ophthalmology.

“For some time, we have been working to evolve from a company with a passive surface modification technology and OEM licensing model to a biotech company with a local drug delivery platform and our own product programs,” Kelley Dealhoy, VP of business development, says in an interview with BioTuesdays. “We are at an inflection point in the process of creating Interface 2.0.”

Read the full article

Briefs
THIS WEEK'S BRIEFS

About Us
ABOUT US

BioTuesdays was created in 2009 by Kilmer Lucas, a leading healthcare-only investor relations firm. Employing a unique "outsourced in-house" partnership model, Kilmer Lucas designs and executes customized IR & PR programs for its drug development, medical device, cell therapy, diagnostics and healthcare services clients. But, most of BioTuesdays' content isn't client-driven. Rather, our mission is to give as many great healthcare companies and their stories as much exposure as we can.

Contact Us
CONTACT US

phone 1-888-545-6374
email info@kilmerlucas.com
Want to be featured in BioTuesdays? Get in touch with us.
Copyright © 2019 Kilmer Lucas, All rights reserved.
You are receiving this email because you signed up for the BioTuesdays newsletter.
Privacy Policy

BioTuesdays
PO Box 297
Carlisle, ON L0R 1H0 

subscribe | unsubscribe | update your preferences